In a major breakthrough, Russian cancer vaccine Enteromix shows 100% success in early trials, giving new hope to patients worldwide. The results were revealed at the 2025 St. Petersburg International Economic Forum. All patients in the study saw tumour shrinkage with no serious side effects.
Russia’s National Medical Research Radiological Centre and the Engelhardt Institute of Molecular Biology created Enteromix. The vaccine uses mRNA technology, the same platform as COVID-19 vaccines, to train the immune system to detect and destroy cancer cells. Unlike chemotherapy, it offers a safer and more precise treatment.
Enteromix stands out because it is fully personalized. Each dose matches the genetic profile of an individual’s tumour, ensuring stronger and more accurate immune responses. The first trial included 48 colorectal cancer patients, and every participant showed positive results.
Experts say Enteromix could reshape cancer care if larger trials confirm its promise. For India, where colorectal and cervical cancer remain leading killers, this vaccine could transform treatment—if costs, regulations, and infrastructure align.
